United States regulator approves Roche’s Covid-19 antibody test
Through a blood sample, the test can detect antibodies to the new coronavirus, which could signal a person may have already been infected.
Copyright 2020 The Associated Press. All Rights Reserved.
The US Food and Drug Administration (FDA) has given emergency approval for use of the serological test developed by Swiss pharmaceutical giant Roche, the company announced on Sunday.
The test is designed to determine whether a person has been exposed to the new coronavirus and developed antibodies against the disease.
The Basel-based firm says that its Elecsys Anti-SARS-CoV-2 test has a specificity rate of 99.8% – which lowers the chance of false positives – and detects antibodies with 100% sensitivity.
Roche has started shipping the new test to laboratories around the world and says it plans to increase production to “high dougle-digit millions per month” to supply countries that accept the CE mark as well as the US.
Scientists worldwide are in a race to develop serological tests, as results can help policy-makers better understand the disease, determine who may have had the virus and who may have immunity, and what measures may still be needed to fight the pandemic.
More
More
Coronavirus: the situation in Switzerland
This content was published on
An overview of the latest Covid-related information in the Alpine nation.
Swiss university graduates are popular hires worldwide
This content was published on
Graduates of Swiss universities are popular with international employers, according to the Global Employability University Rankings.
French cross-border workers in Switzerland fear ‘discriminatory’ unemployment reform
This content was published on
In the French region around Geneva, cross-border workers are protesting proposals to cut unemployment benefits for those working in Switzerland.
Swan infected with bird flu in central Switzerland
This content was published on
Switzerland has reported its first bird flu case of the season. A swan found dead in central Switzerland tested positive for the H5N1 virus.
Swiss researchers identify gene variants linked to cancer progression
This content was published on
ETH Zurich researchers explored genetic mutations’ effects on cell function and their role in cancer development and treatment using CRISPR/Cas techniques.
Explosion at Swiss company Givaudan’s US plant leaves two dead
This content was published on
Swiss flavour and fragrance maker Givaudan reported that an explosion at its Kentucky plant resulted in two deaths and several injuries.
Swisscom’s Vodafone Italia takeover cleared by Italian telecoms authority
This content was published on
Swisscom is one step closer to its planned acquisition of Vodafone Italia, as the Italian communications regulator has approved the €8 billion deal.
Swiss parliamentary committee proposes foreign aid cuts and military funding boost
This content was published on
A committee of the Swiss House of Representatives has proposed increasing funds for the military and agriculture while reducing foreign aid and asylum.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
What Swiss researchers are doing to beat Covid-19
This content was published on
Swiss scientists and drug companies are playing an important role in the global effort to develop treatments or a vaccine for the virus.
This test could help Switzerland get back on track
This content was published on
While we await a vaccine or treatment, scientists are developing tests to tell us how widespread the virus is, such as the serological test.
Covid-19 immunity testing to begin in some Swiss hospitals
This content was published on
The hospitals are planning to roll out testing to evaluate how many people have already been infected, including those who may have already be immune.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.